SHINE Technologies宣布计划收购 Lantheus的 SPECT部门，扩大其在核医学领域的市场覆盖和领导地位SHINE Technologies Announces Plan to Acquire Lantheus' SPECT Division, Expanding Market Reach and Leadership in Nuclear Medicine

动脉网2025-05-07

Strategic acquisition enhances SHINE's distribution channels and strengthens access to cleaner, safer and more reliable medical isotopes战略性收购增强了SHINE的分销渠道，并加强了获取更清洁、更安全和更可靠的医用同位素的能力。JANESVILLE, Wis.简...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2533618817?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-07 04:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2533618817","market":"us","top_or_hot":-1,"title":"SHINE Technologies宣布计划收购 Lantheus的 SPECT部门，扩大其在核医学领域的市场覆盖和领导地位SHINE Technologies Announces Plan to Acquire Lantheus' SPECT Division, Expanding Market Reach and Leadership in Nuclear Medicine","media":"动脉网","content":"<div>\n<p>Strategic acquisition enhances SHINE's distribution channels and strengthens access to cleaner, safer and more reliable medical isotopes战略性收购增强了SHINE的分销渠道，并加强了获取更清洁、更安全和更可靠的医用同位素的能力。JANESVILLE, Wis.简...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050708200994ee821c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SHINE Technologies宣布计划收购 Lantheus的 SPECT部门，扩大其在核医学领域的市场覆盖和领导地位SHINE Technologies Announces Plan to Acquire Lantheus' SPECT Division, Expanding Market Reach and Leadership in Nuclear Medicine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSHINE Technologies宣布计划收购 Lantheus的 SPECT部门，扩大其在核医学领域的市场覆盖和领导地位SHINE Technologies Announces Plan to Acquire Lantheus' SPECT Division, Expanding Market Reach and Leadership in Nuclear Medicine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-07 04:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050708200994ee821c&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Strategic acquisition enhances SHINE's distribution channels and strengthens access to cleaner, safer and more reliable medical isotopes战略性收购增强了SHINE的分销渠道，并加强了获取更清洁、更安全和更可靠的医用同位素的能力。JANESVILLE, Wis.简...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050708200994ee821c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050708200994ee821c&s=b","article_id":"2533618817","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050708200994ee821c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2533618817","pubTimestamp":1746561660,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"此次收购将包括North Billerica, Massachusetts北比勒里卡，马萨诸塞州campus that manufactures Lantheus' SPECT products.生产兰索斯SPECT产品的校园。SHINE and Lantheus share a commitment to ensuring consistent patient access to critical medical isotopes. By combining SHINE's fusion-based isotope manufacturing technology with Lantheus' established market channels, the transaction creates powerful synergies that strengthen SHINE's leadership in the nuclear medicine market..SHINE 和 Lantheus 坚信要确保患者持续获得关键的医用同位素。通过将 SHINE 基于聚变的同位素制造技术与 Lantheus 已建立的市场渠道相结合，此次交易创造了强大的协同效应，巩固了 SHINE 在核医学市场的领导地位。Lantheus的SPECT产品组合包括用于心脏、肺、甲状腺、膀胱等","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","LNTH":"Lantheus Holdings, Inc.","BK4585":"ETF&股票定投概念","BK4198":"医疗保健用品"},"translate_title":"SHINE Technologies announces plans to acquire Lantheus' SPECT division, expanding its market coverage and leadership in nuclear medicine SHINE Technologies Announces Plan to Acquire Lantheus' SPECT Division, Expanding Market Reach and Leadership in Nuclear Medicine","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LNTH":0.9},"content_text":"Strategic acquisition enhances SHINE's distribution channels and strengthens access to cleaner, safer and more reliable medical isotopes战略性收购增强了SHINE的分销渠道，并加强了获取更清洁、更安全和更可靠的医用同位素的能力。JANESVILLE, Wis.简斯维尔，威斯康星州,，May 6, 20252025年5月6日/PRNewswire/ --/PRNewswire/ --SHINE Technologies闪亮科技, a nuclear fusion company with a platform of medical isotope products, announced it has entered into a definitive agreement to acquire the SPECT business from Lantheus, a leading radiopharmaceutical-focused company. The acquisition will include the portion of the，一家拥有医疗同位素产品平台的核聚变公司，宣布已达成最终协议，将收购专注于放射性药物的领先公司 Lantheus 的 SPECT 业务。此次收购将包括North Billerica, Massachusetts北比勒里卡，马萨诸塞州campus that manufactures Lantheus' SPECT products.生产兰索斯SPECT产品的校园。Continue Reading继续阅读Chrysalis, SHINE’s large-scale irradiation facility, is set to become the largest isotope production facility in the world. Once operational, Chrysalis will complement the existing supply chain ensuring a sustainable and reliable source of isotopes, including Mo-99, the world’s most widely-used isotope, and Lu-177, the most widely-used cancer-fighting isotope..Chrysalis 是 SHINE 的大规模辐照设施，将成为世界上最大的同位素生产设施。一旦投入运营，Chrysalis 将补充现有的供应链，确保可持续且可靠的同位素来源，包括全球应用最广泛的同位素钼-99 (Mo-99) 和应用最广泛的抗癌同位素镥-177 (Lu-177)。SHINE and Lantheus share a commitment to ensuring consistent patient access to critical medical isotopes. By combining SHINE's fusion-based isotope manufacturing technology with Lantheus' established market channels, the transaction creates powerful synergies that strengthen SHINE's leadership in the nuclear medicine market..SHINE 和 Lantheus 坚信要确保患者持续获得关键的医用同位素。通过将 SHINE 基于聚变的同位素制造技术与 Lantheus 已建立的市场渠道相结合，此次交易创造了强大的协同效应，巩固了 SHINE 在核医学市场的领导地位。'Today's announcement marks a major milestone on our journey to improve lives through fusion technology,' said“今天的公告标志着我们通过核聚变技术改善生活的旅程中的一个重要里程碑，”Greg Piefer格雷格·皮费尔, founder and CEO of SHINE. 'Our companies have a long history of partnership, and we have admired Lantheus' commitment to ensuring patient access to essential medical radioisotopes. By integrating Lantheus' SPECT business and talented team with our company, we will expand our product portfolio, accelerate our path to market for our planned suite of isotopes and increase our market share – ultimately ensuring greater access to these life-saving products for patients.'.SHINE创始人兼首席执行官表示：“我们的公司有着长期的合作历史，我们一直钦佩Lantheus致力于确保患者获得必要的医用放射性同位素。通过将Lantheus的SPECT业务和优秀团队整合到我们的公司，我们将扩展我们的产品组合，加速我们计划中的同位素套件的上市进程，并增加我们的市场份额 —— 最终确保患者能够更广泛地获得这些挽救生命的产品。”For nearly 70 years, Lantheus has provided the nuclear medicine market with first-in-class diagnostic radiopharmaceutical products. The company is a market leader in US production of technetium-99 (Tc-99), a medical isotope used in nuclear medicine imaging procedures. Lantheus' SPECT product portfolio includes imaging agents for the heart, lung, thyroid, bladder and more..近70年来，Lantheus一直为核医学市场提供一流的诊断放射性药物产品。该公司是美国生产锝-99（Tc-99）的市场领导者，锝-99是一种用于核医学成像程序的医用同位素。Lantheus的SPECT产品组合包括用于心脏、肺、甲状腺、膀胱等的显像剂。Chrysalis, SHINE's large-scale irradiation facility, is set to become the largest isotope production facility in the world. Once operational, Chrysalis will complement the existing supply chain ensuring a sustainable and reliable source of isotopes, including Mo-99, the world's most widely-used isotope, and Lu-177, the most widely-used cancer fighting isotope..Chrysalis 是 SHINE 的大规模辐照设施，将成为世界上最大的同位素生产设施。一旦投入运营，Chrysalis 将补充现有供应链，确保包括全球应用最广泛的同位素钼-99（Mo-99）和应用最广泛的抗癌同位素镥-177（Lu-177）在内的可持续且可靠的同位素来源。Last year, SHINE opened one of the largest facilities in the western hemisphere dedicated to producing non-carrier-added lutetium-177. The facility has a production capacity of up to 100,000 doses of Lu-177 per year, with the ability to further expand to 200,000 doses per year.去年，SHINE 开设了西半球最大的无载体添加镥-177生产设施之一。该工厂每年可生产多达10万剂Lu-177，并具备进一步扩展至每年20万剂的能力。'We are confident that SHINE's expertise in isotope production as well as their commitment to growth and patient access position them well to continue our legacy with the SPECT business as we focus on advancing and expanding our pipeline of innovative diagnostics and therapeutics,' said“我们相信，SHINE在同位素生产方面的专业知识以及他们对增长和患者获取的承诺，使他们有能力在我们专注于推进和扩展我们的创新诊断和治疗产品线时，继续我们在SPECT业务中的传承，”Brian Markison布赖恩·马基里森, CEO of Lantheus. 'SHINE's interest in our SPECT business underscores the dedication and knowledge of our employees who have been instrumental to its decades-long success at Lantheus, and we thank our talented team for their contributions.'兰泰公司的首席执行官表示：“SHINE 对我们的 SPECT 业务感兴趣，这凸显了我们员工的奉献精神和专业知识，他们对兰泰公司几十年来的成功起到了关键作用，我们感谢我们才华横溢的团队所做出的贡献。”About SHINE关于SHINEHeadquartered in总部位于Janesville, Wisconsin威斯康星州简斯维尔, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, cost-efficiency and environmental responsibility.，SHINE 是下一代聚变领域的行业领导者，正在开发基于聚变的创新技术，该技术结合了安全性、成本效益和环境责任。SHINE has successfully commercialized fusion across multiple applications, including neutron testing markets such as neutron radiography, radiation-effects testing and fusion material research. It has commercialized and is scaling its proprietary medical isotope production, processes, supplying high-quality radioisotopes essential for procedures including diagnosing heart disease and cancer as well as cancer therapy..SHINE已成功在多个应用领域实现聚变商业化，包括中子测试市场，如中子射线照相、辐射效应测试和聚变材料研究。该公司已经实现并正在扩展其专有的医用同位素生产流程，供应高质量的放射性同位素，这些同位素对于诊断心脏病、癌症以及癌症治疗等程序至关重要。Beyond these applications, SHINE is pioneering nuclear waste recycling to make nuclear energy more sustainable. Its long-term purpose is to change the way humans make energy by commercializing fusion energy. Unlike other fusion companies, SHINE takes a commercially driven path mirroring successful deep-tech industries.除了这些应用之外，SHINE 正在引领核废料回收，以使核能更加可持续。其长期目标是通过商业化聚变能源改变人类生产能源的方式。与其他聚变公司不同，SHINE 采取了一条类似于成功深科技行业的商业化驱动路径。Through this visionary approach, SHINE is advancing technology, healthcare, and sustainable energy, making a lasting impact across multiple sectors..通过这一富有远见的方法，SHINE正在推动技术、医疗保健和可持续能源的发展，在多个领域产生持久影响。SOURCE SHINE Technologies, LLC源光辉科技有限公司WANT YOUR COMPANY'S NEWS想要你公司的新闻吗FEATURED ON PRNEWSWIRE.COM?刊登在PRNEWSWIRE.COM上？440k+44万+Newsrooms &新闻编辑室 &Influencers影响者9k+9k+Digital Media数字媒体Outlets插座270k+27万+Journalists记者Opted In已选择加入GET STARTED开始使用","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2533618817","isCrawlerRequest":true}